Burkitt-Type Acute Lymphoblastic Leukemia in Donor Cells After Allogeneic Bone Marrow Transplantation for Acute Nonlymphoblastic Leukemia

Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia

“…During the last 15 years several studies have utilized molecular and molecular cytogenetic methods in combination with routine cytogenetic analysis to differentiate DCL from host leukaemia relapse. 5,6 In the patient reported here the post-transplant secondary acute leukaemia appeared to be myeloid in type and derived from donor cells. The donor origin of haemopoiesis has been proved by the donor-type RBC blood group, the presence of XX sex chromosome, and the absence of the Ph chromosome in the BM cells both by traditional and interphase cytogenetic analysis.…”

“…In addition, the sorted CD34 ϩ cells proved to give two X or even 4 X sig- Seventeen cases of DCL have previously been reported after BMT for leukaemia and two cases after transplant for benign disease. [2][3][4][5][6][7] The 19 cases of DCL include 11 female and eight male patients with a median age of 19.6 years (range 3-43). The time interval from BMT to diagnosis of DCL ranged from 2 to 135 months (median 33 months).…”

“…[5][6][7] We report the case of a male patient with Ph chromosome and bcr-abl positive chronic phase chronic myeloid leukaemia who developed AML of donor origin 5 years after allogeneic BMT from his HLA-matched sister.…”

Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia

“…Although Boyd et al suggested that DCL accounted for approximately 5% of relapses on the basis of cytogenetic studies of 54 relapses in sex-mismatched bone marrow transplants [1], in an EBMT survey, the occurrence rate is reported as 14 cases in 10,489 transplants between 1982 and 2003 [2]. Several hypotheses have been offered to date to explain how DCL might arise: occult leukemia in the donor [3], transfer of oncogenic material from host to donor cells [4], impaired immune surveillance [5], incorrect identification of origin of leukemic cells, or leukemic transformation of engrafted bone marrow cells [6,7].…”

B-cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation

“…Only a few case reports have described the occurrence of leukemia in donor cells. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] In most of the reports, the donor was a matched sibling, and the transplant was performed for malignant disease (acute or chronic leukemia), suggesting a genetic predisposition for the development of the donororigin malignancy. The fact that in most of the cases described the donor has had no evidence of leukemia either before or after the development of malignancy in the transplanted cells indicates that transplant-related factors are most likely to be responsible for the development of the leukemia in the donor cells.…”